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RESEARCH
Balanced impacts of fitness and drug 
pressure on the evolution of PfMDR1 
polymorphisms in Plasmodium falciparum
Marvin Duvalsaint1†, Melissa D. Conrad1†, Stephen Tukwasibwe2, Patrick K. Tumwebaze2, Jennifer Legac1, 
Roland A. Cooper3 and Philip J. Rosenthal1*  
Abstract 
Background: Anti-malarial drug resistance may be limited by decreased fitness in resistant parasites. Important con-
tributors to resistance are mutations in the Plasmodium falciparum putative drug transporter PfMDR1.
Methods: Impacts on in vitro fitness of two common PfMDR1 polymorphisms, N86Y, which is associated with sensi-
tivity to multiple drugs, and Y184F, which has no clear impact on drug sensitivity, were evaluated to study associations 
between resistance mediators and parasite fitness, measured as relative growth in competitive culture experiments. 
NF10 P. falciparum lines engineered to represent all PfMDR1 N86Y and Y184F haplotypes were co-cultured for 40 days, 
and the genetic make-up of the cultures was characterized every 4 days by pyrosequencing. The impacts of culture 
with anti-malarials on the growth of different haplotypes were also assessed. Lastly, the engineering of P. falciparum 
containing another common polymorphism, PfMDR1 D1246Y, was attempted.
Results: Co-culture results were as follows. With wild type (WT) Y184 fixed (N86/Y184 vs. 86Y/Y184), parasites WT and 
mutant at 86 were at equilibrium. With mutant 184 F fixed (N86/184F vs. 86Y/184F), mutants at 86 overgrew WT. With 
WT N86 fixed (N86/Y184 vs. N86/184F), WT at 184 overgrew mutants. With mutant 86Y fixed (86Y/Y184 vs. 86Y/184F), 
WT and mutant at 86 were at equilibrium. Parasites with the double WT were in equilibrium with the double mutant, 
but 86Y/Y184 overgrew N86/184F. Overall, WT N86/mutant 184F parasites were less fit than parasites with all other 
haplotypes. Parasites engineered for another mutation, PfMDR1 1246Y, were unstable in culture, with reversion to WT 
over time. Thus, the N86 WT is stable when accompanied by the Y184 WT, but incurs a fitness cost when accompa-
nied by mutant 184F. Culturing in the presence of chloroquine favored 86Y mutant parasites and in the presence of 
lumefantrine favored N86 WT parasites; piperaquine had minimal impact.
Conclusions: These results are consistent with those for Ugandan field isolates, suggest reasons for varied haplo-
types, and highlight the interplay between drug pressure and fitness that is guiding the evolution of resistance-medi-
ating haplotypes in P. falciparum.
Keywords: Malaria, Plasmodium falciparum, Drug resistance, Fitness, PfMDR1
© The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, 
adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and 
the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material 
in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material 
is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the 
permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco 
mmons. org/ licen ses/ by/4. 0/. The Creative Commons Public Domain Dedication waiver (http:// creat iveco mmons. org/ publi cdoma in/ 
zero/1. 0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Malaria remains an enormous problem in tropical 
regions despite extensive efforts to control and elimi-
nate the disease [1]. Malaria is particularly devastat-
ing in Africa, where the vast majority of cases are due 
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malaria parasite [2]. With development of resistance 
to older drugs, standard therapy for falciparum malaria 
in Africa moved to artemisinin-based combination 
therapy (ACT) early this century [3]. ACT, including 
artemether-lumefantrine, artesunate-amodiaquine, dihy-
droartemisinin-piperaquine, artesunate-mefloquine, and 
artesunate-pyronaridine, combines a potent and fast-
acting artemisinin derivative with a slower acting partner 
drug [4]. Partner drugs play a key role in assuring the effi-
cacy of ACT, by eliminating remaining parasites after the 
short acting artemisinins are cleared, and by protecting 
against emergence of artemisinin resistance. However, 
resistance to artemisinins in southeast Asia [5] and var-
ied activity of most partner drugs [6] threatens the effi-
cacy of ACT. Interestingly, widely used partner drugs 
have opposing drug sensitivity profiles, with decreased 
sensitivity to amodiaquine (a close relative of chloro-
quine) associated with increased sensitivity to lumefan-
trine and mefloquine [7].
Varied sensitivities to some ACT partner drugs corre-
late with polymorphisms in putative drug transporters 
[8]. The 76T mutation in the P. falciparum chloroquine 
resistance transporter (PfCRT) is associated with resist-
ance to chloroquine and amodiaquine [9, 10], and the 
K76 wild type is associated with decreased sensitivity to 
lumefantrine and mefloquine [10]. The PfCRT 76T muta-
tion was previously widespread in Africa [11], but preva-
lence has decreased with replacement of chloroquine by 
artemether-lumefantrine as the first-line anti-malarial. 
Mutations in a second putative drug transporter, the 
ATP-binding cassette protein PfMDR1, also impact on 
drug sensitivity [12, 13]. In particular, PfMDR1 N86Y has 
the same pattern of association as PfCRT K76T, with the 
86Y mutation associated with decreased sensitivity to 
chloroquine and amodiaquine [10, 14], and selected by 
therapy with amodiaquine [15–17], and the N86 wild type 
associated with decreased sensitivity to lumefantrine and 
mefloquine [10, 14], and selected by therapy with lume-
fantrine [16–19]. As seen for PfCRT 76T, the prevalence 
of PfMDR1 86Y has decreased markedly in many regions 
in recent years [11]. Two other common PfMDR1 muta-
tions in Africa, 184F and 1246Y, have uncertain associa-
tions with drug sensitivity, although 1246Y was selected 
by therapy with artesunate-amodiaquine [15] and asso-
ciated with decreases in both amodiaquine sensitivity 
and fitness in vitro [20]. Increased pfmdr1 copy number 
is associated with decreased sensitivity to mefloquine 
and lumefantrine [21, 22], but increased copy number is 
uncommonly seen in African parasites [23–25].
Changes in the prevalence of key transporter muta-
tions with changes in drug utilization suggest a complex 
interplay between mediators of drug sensitivity and para-
site fitness in determining genotypes now circulating in 
Africa. However, the impacts of PfMDR1 haplotypes on 
P. falciparum fitness are uncertain. In co-culture experi-
ments, wild type parasites outgrew parasites with four 
introduced PfMDR1 mutations (184F, 1034C, 1042D, 
1246Y) [26] and with amplification of pfmdr1 [27]. How-
ever, these experiments did not consider the PfMDR1 
86Y mutation, which appears to be the key drug sen-
sitivity mediator for this protein in Africa. In a study in 
the Gambia before the advent of ACT, the prevalence 
of PfMDR1 N86 wild type parasites was greater at the 
beginning of the transmission season than later in that 
season, consistent with a selective advantage for the wild 
type parasites when selective drug pressure (primar-
ily from chloroquine) was limited [28]. However, in two 
studies culture of polyclonal Ugandan field isolates with 
mixed pfmdr1 genotypes showed, surprisingly, supe-
rior growth of the mutant 86Y allele in culture over time 
[29, 30]. Based on these results, it was hypothesized that 
mutant 86Y parasites are more fit than wild type due to 
epistasis with other mutations in the PfMDR1 gene. To 
test this hypothesis, isogenic lines engineered to contain 
known African PfMDR1 haplotypes in co-culture experi-
ments were utilized, allowing direct evaluation of the 
impact of PfMDR1 mutations on parasite fitness, with fit-
ness assessed by competitive in vitro growth.
Methods
Plasmodium falciparum culture
Plasmodium falciparum NF10 parasites with introduced 
PfMDR1 N86Y and Y184F mutations [14] (generously 
provided by M. Isabel Veiga and David Fidock, Columbia 
University) were cultured in complete medium consist-
ing of RPMI-1640 (Invitrogen) supplemented with 0.5% 
Albumax II (GIBCO Life Technologies), 0.2% sodium 
bicarbonate, 100 µM hypoxanthine, 2 mM l-glutamine, 
5 ug/mL gentamycin, and 25 mM HEPES at 2% haema-
tocrit at 37 °C in an atmosphere of 5%  O2, 5%  CO2, and 
90%  N2.
Growth competition experiments
Parasites were synchronized at the ring stage using 5% 
(wt/vol) D-sorbitol (Sigma-Aldrich) [31] and washed 
three times with RPMI medium. Infected erythrocytes 
were stained with SYTO-16 (Thermo Fisher Scientific), 
and counts were obtained with flow cytometry. Co-cul-
tures (2.5 mL) were prepared by mixing two lines at equal 
parasitaemia at an initial total parasitaemia of 0.5% in the 
culture conditions noted above. Media was changed and 
dilutions made to maintain a parasitaemia of ~ 0.5% every 
2 days. For each combination studied, 2–6 independent 
experiments were maintained for 32 to 40 days.
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Co‑culture with anti‑malarials
Parasites were cultured with varied concentrations of 
chloroquine (Sigma-Aldrich), lumefantrine (a gift from 
the Medicines for Malaria Venture), and piperaquine 
(Jinan Jiaquan International Trade Co.), both with con-
tinuous and intermittent exposure to the drugs, to iden-
tify maximum concentrations that allowed growth in 
culture. Parasites were then co-cultured in the indicated 
concentrations of the anti-malarials, with cycles of 2 days 
with and 2 days without the drugs, and culture conditions 
and maintenance of parasitaemia at ~ 0.5%, as described 
above.
Genetic analysis of cultured parasites
Culture aliquots were collected and stored as dried blood 
spots on Whatman 3 MM filter paper every 4 days. DNA 
was extracted with Chelex 100, as previously described 
[32]. The ratios of co-cultured lines was determined by 
pyrosequencing of extracted DNA samples by EpigenDx 
(Hopkinton, MA), following methods as previously 
described [30]. In brief, biotinylated PCR products were 
bound to streptavidin beads and converted to single-
stranded DNA sequencing templates, and the single-
stranded DNA was sequenced with previously published, 
position-specific primers [30] using a pyrosequencing 
PSQ96 HS system following the manufacturer’s instruc-
tions (Qiagen). Every pyrosequencing run included 
negative and positive controls with known sequence; as 
pyrosequencing data are provided within a sequence con-
text, the likelihood of false reads is low. The sequences 
of each sample were analysed using PSQ software, and 
alleles were quantified as the percentage of each base at 
sites of interest.
Statistical analysis
The ratio of the percentage of each base at sites of inter-
est for each pyrosequenced sample was natural log-trans-
formed and used to calculate the fitness (ω’) of the 











+ tln(ω) . The relative fitness index (ω’) 
for the mutant variant in each competition assay was 
determined from the slope of the least-squared regres-
sion plot of log(pt /qt) against t, where t is time measured 
as asexual generations (2 days), pt is the frequency of the 
wild-type variant at each generation, and qt is the fre-
quency of the mutant variant [33]. Data from multiple 
competition assays were utilized in fitting this linear rela-
tionship. Selection coefficients were then derived from ω’ 
as per the relationship s = ω’ – 1, such that s > 0 indicates 
inferior growth of the mutant and s < 0 indicates superior 
growth of the mutant compared to that of the wild type. 
Statistical significance was assessed using RStudio [34]. A 
one-way ANOVA test was used to determine the statisti-
cal significance of s differing from 0, and a two-way 
ANOVA with Tukey’s post-hoc test to compare s in the 
presence or absence of drug. P-values < 0.05 were consid-
ered significant.
CRISPR‑Cas9‑mediated editing of pfmdr1
Editing was performed based on a strategy and meth-
ods described previously [35]. Plasmids pCas9-gRNA-
hdhfr and pT7Pol-bsd containing gRNA8, a guide RNA 
that was previously demonstrated to be effective in 
editing other nucleotides in pfmdr1 [35] and is located 
481 nucleotides downstream of the target, were kindly 
provided by Caroline L. Ng and David Fidock, Colum-
bia University. These express human dihydrofolate 
reductase (dhfr) and blasticidin S-deaminase selecta-
ble markers, respectively. A 1.4  kb fragment of donor 
template encoding mutant (1246Y) PfMDR1 was ampli-
fied from genomic DNA using 5′-GAG CTC GTA TTT 
GCT GTA AGA GCT AGA TTA A-3′ (SacI restriction site 
underlined) and 5′-GAC GTC TTT AGC TAA TTT TAC 
ATA TTT TTT ATA TAT TCC-3′ (AatII restriction site 
underlined). The Q5 Site‐Directed Mutagenesis Kit 
(NEB) and primers p4358 (5′-CAA GTT GAT GAG TTT 
GAA GGG AGA TTC AGA AAA TGC AAA ATT ATC-3′) 
and p4359 (5′-CCA GCA TAA CTA CCA GTA AAT ATA 
AAA GTA AAT AAG -3′) were used to introduce silent 
mutations at the Cas9 binding site to prevent Cas9 
cleavage of the plasmid or the edited gene. The result-
ing segment was then inserted into the pT7Pol‐bsd 
Table 1 NF10 haplotypes studied in competitive growth experiments
The haplotypes shown indicate the N86Y and Y184F sequences. Drug sensitivities are as reported previously [14]
Haplotype PfMDR1 sequence Drug sensitivity  (IC50, nM)
86 184 Chloroquine Lumefantrine Piperaquine
NY Wild type Wild type 185 3.2 28.9
NF Wild type Mutant 205 3.2 35.1
YY Mutant Wild type 331 0.9 35.4
YF Mutant Mutant 328 0.9 40.2
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plasmid using the SacI and AatII restriction sites. Syn-
chronized ring stage NF10 parasites at 5% parasitaemia 
were electroporated with 50–100  µg pCas9-gRNA-
hdhfr and pT7Pol bsd plasmids in 800 µL cytomix 
according to previously published methods [35]. Blas-
ticidin S HCl (2 µg/mL; Santa Cruz Biotechnology) and 
WR99210 (2.5 nM; Sigma-Aldrich) were supplemented 
24  h post-electroporation for 6 days, followed by cul-
ture in drug free media. By day 21–28, parasites were 
seen on smears, parasite DNA was Sanger sequenced 
(Eurofin Genomics), and parasites were cloned via 
limiting dilution to 0.5 parasites per well in 96-well 
plates for a total volume of 200 µL. Media was changed 
weekly, and thick smears were prepared on day 14 and 
then weekly. Wells positive for parasites were expanded 
to 500 µL cultures in 24-well plates, and DNA was 
extracted and sequenced using primers 1246 F (5′- ATG 
ATC ACA TTA TAT TAA AAA ATG ATA TGA CAAAT-
3′) and MDR-O2 (5′- ATG ATT CGA TAA ATT CAT CTA 
TAG CAG CAA -3′). Sequencing results were compared 




Plasmodium falciparum strain NF10, the product of a 
genetic cross between the Brazilian 7G8 and Ghana-
ian GB4 strains, was engineered previously to pro-
vide lines wild type or mutant at PfMDR1 N86Y and 
Y184F, loci that have been polymorphic in African 
parasites [14] (Table  1). Considering other common 
polymorphisms relevant to drug resistance, NF10 para-
sites have wild type (based on strain 3D7) sequence at 
PfMDR1 positions 1034, 1042, and 1246; have one copy 
of the pfmdr1 gene; and contain the PfCRT position 
72–76 CVIET haplotype and 5 other PfCRT mutations 
(A220S, Q271E, N326S, I356T, and R371I), a genotype 
associated with resistance to chloroquine [36]. Lines 
with all possible combinations of PfMDR1 N86Y and 
Y184F were subjected to competition experiments, in 
which equal quantities of two lines were co-cultured 
for 40 days, and the proportion of each line was quan-
tified by pyrosequencing every 4 days (Fig.  1). Rela-
tive growth estimates were characterized based on the 
ability of a line to outgrow the co-cultured line over 40 
days, and used to derive per-generation relative selec-
tion coefficients (s) for wild type alleles in each compet-
itive growth experiment (Table 2).
Impact of N86Y on parasite fitness
With the wild type Y184 sequence fixed, parasites wild 
type or mutant at position 86 were in equipoise (Fig. 1A, 
Table  2). With the mutant 184  F sequence fixed, para-
sites mutant at position 86 overgrew wild type parasites 
(Fig.  1B; Table  2). Considering lines differing at both 
positions, 86Y/Y184 parasites overgrew N86/184F para-
sites (Fig. 1C, Table 2) and N86/Y184 and 86Y/184F para-
sites were in equipoise (Fig. 1D; Table 2). Taken together, 
these results suggest that the N86Y polymorphism has 
limited impact on parasite fitness when the 184 sequence 
is wild type, but that in the setting of the 184 F mutation, 
surprisingly, mutant 86Y parasites are more fit than those 
wild type at position 86.
Impact of Y184F on parasite fitness
With the wild type N86 sequence fixed, parasites wild 
type at position 184 overgrew those mutant at this posi-
tion (Fig.  1E; Table  2). With the mutant 86Y sequence 
fixed, parasites wild type or mutant at position 184 were 
in equipoise (Fig.  1F, Table  2). Taken together, these 
results suggest that in the setting of the N86 wild type 
sequence, parasites with the Y184 wild type polymor-
phism are more fit than those with a mutation at this 
position.
Table 2    In vitro growth selection coefficients for co-cultured PfMDR1 variants
The haplotypes shown indicate the N86Y and Y184F sequences. The per-generation selection coefficient (s) was derived from the relative fitness index (ω’) as per the 
relationship s = ω’ – 1, such that s < 0 and s > 0 indicate inferior and superior growth of the wild-type allele, respectively. s was considered to differ significantly from 0 
when Pr(>|t|) was ≤ 0.05. N, number of independent growth competition assays analysed
Haplotype 
combination
N PfMDR1 N86 PfMDR1 Y184
s Pr(>|t|) s Pr(>|t|)
NY vs. YY 5 − 0.02 0.39 – –
NF vs. YF 3 − 0.12 < 0.0001 – –
NF vs. YY 3 − 0.09 < 0.0001 0.09 0.008
NY vs. YF 4 − 0.04 0.07 − 0.04 0.06
NY vs. NF 4 – – 0.13 < 0.0001
YY vs. YF 3 – – − 0.03 0.17
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Fig. 1   Relative fitness of parasites with varied PfMDR1 sequences. Combinations of PfMDR1 N86Y and Y184F haplotypes were co-cultured in 
competitive growth experiments, beginning with equal quantities of the two lines, and relative fitness was assessed based on the prevalence of 
each genotype over 40 days, with the percentage of wild type shown for the loci that differed between the two lines. Each line is designated based 
on the amino acid at positions 86 and 184. Co-culture experiments demonstrated three lines in equipoise (A, D, F), overgrowth of mutant parasites 
(B), overgrowth of wild-type parasites (E), and selection of wild type/mixed 86Y/Y184 parasites (C). * Indicates combinations with statistically 
significant selection coefficients
Fig. 2   Transfection of PfMDR1 1246Y over time. Sequence traces for 4 independent transfections are displayed (A–D). Sequencing was conducted 
3–4 weeks post-transfection and then weekly during cloning and expansion. The sequences shown are for amino acids 1244 to 1248. Nucleotides 
highlighted in blue and with a vertical line represent those subject to the T to G substitution that corresponds to a tyrosine (Y, mutant) to aspartic 
acid (D, wild type) substitution
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Impact of D1246Y on parasite fitness
NF10 parasites engineered to carry the PfMDR1 1246Y 
mutation were previously unavailable. Engineering the 
1246Y mutation into NF10 parasites with and with-
out mutations at N86Y and Y184F was attempted using 
the CRISPR Cas9 system, with 6 days of selective drugs 
to maintain transfected plasmids followed by culture 
in drug-free media. By day 21–28, parasites were seen 
on smears and cloned by limiting dilution, and parasite 
DNA was isolated and sequenced weekly. In multiple 
experiments, despite successful integration, parasites 
with 1246Y were not stable in culture. Consistently, the 
mutant sequence was replaced by wild type over time 
(Fig.  2). Presumably, despite limiting dilution these cul-
tures contained > 1 parasite clone, allowing overgrowth 
over time of more fit wild type parasites that were initially 
at too low abundance to be recognized by sequencing. As 
numerous other diluted cultures contained no parasites, 
but none had persistence of mutant parasites, it appears 
that the 1246Y mutation incurs a substantial fitness cost, 
regardless of N86Y/Y184F haplotype, when introduced in 
an NF10 background.
Impacts of anti‑malarials on parasite fitness
Co-culture experiments considering different PfMDR1 
86 sequences (N86/Y184 vs. 86Y/Y184 parasites) were 
performed in the presence of selective concentrations (50 
and 25%  IC50 for chloroquine and lumefantrine and 25% 
 IC50 for piperaquine) of anti-malarials. During co-culture 
with chloroquine, parasites with the 86Y mutation over-
grew those wild type at this locus (Fig. 3; Table 3). Dur-
ing co-culture with lumefantrine, wild type N86 parasites 
overgrew mutant parasites. During co-culture with pipe-
raquine, mutant and wild type parasites were in equilib-
rium. Overall, anti-malarials modified the impacts on 
fitness of the N86Y polymorphism in a manner consist-
ent with selections seen in clinical studies (Table 4).
Discussion
The in  vitro fitness of P. falciparum lines with different 
PfMDR1 genetic polymorphisms that have been linked 
to sensitivity to key anti-malarial drugs was compared 
[12, 13]. Surprisingly, the PfMDR1 86Y mutation, which 
Fig. 3   Impact of anti-malarials on fitness of parasites with varied PfMDR1 sequences. With wild-type fixed at PfMDR1 184, parasites wild-type or 
mutant at 86 (NY vs. YY) were co-cultured in the presence of the indicated concentrations of chloroquine (A), lumefantrine (B), or piperaquine (C) 
and the prevalence of each genotype was followed over 36 days. It is seen that mutant parasites are favored under chloroquine pressure, wild type 
parasites are favored under lumefantrine pressure, and that there is no clear impact on genotype prevalence under piperaquine pressure
Table 3 In vitro growth selection coefficients for PfMDR1 
variants (NY vs. YY) co-cultured in the presence of anti-malarials
Analysis was as described for Table 1. Ps, P value for comparison of s to 0. Pd, P 
value for comparison of s for assays performed in the presence or absence of 
anti-malarials. Ps was determined using one-way ANOVA. Pd was determined 
using two-way ANOVA with Tukey’s post-hoc test
Drug exposure s Ps Pd
No drug − 0.02 0.20 -
Chloroquine
 80 nM, 25%  IC50 − 0.04 0.0006 0.67
 160 nM, 50%  IC50 − 0.08 0.001 0.03
Lumefantrine
 0.5 nM, 25%  IC50 0.49 0.003 < 0.0001
 1 nM, 50%  IC50 0.43 0.0008 < 0.0001
Piperaquine
 9 nM, 25%  IC50 − 0.05 0.08 0.63
Table 4 Summary of selection results
The haplotypes shown indicate the N86Y and Y184F sequences
Selective pressure Selected against Selected for
  None NF NY, YF, YY
  Chloroquine NY YY
  Lumefantrine YY NY
  Piperaquine No selection
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mediates decreased sensitivity to chloroquine and amo-
diaquine independent of mutations in pfcrt [10, 14], but 
increased sensitivity to lumefantrine and mefloquine, 
was associated with enhanced fitness compared to wild 
type, but only in the presence of the 184F mutation. Like-
wise, the wild type Y184 sequence was favored, except in 
the presence of the 86Y mutation. A third PfMDR1 muta-
tion that has been common in parts of Africa, 1246Y, was 
unstable in culture. Culture with anti-malarials stabilized 
polymorphisms previously associated with decreased 
sensitivity to those drugs. Taken together, these results 
suggest a complex interplay between PfMDR1 mutations 
and parasite fitness, consistent with the changes in anti-
malarial therapy and P. falciparum genotypes seen in 
Africa in recent years.
Plasmodium falciparum genotypes associated with sen-
sitivity to key ACT partner drugs have changed remarka-
bly in Africa over the last decade. Notably, the prevalence 
of two polymorphisms that are associated with decreased 
sensitivity to chloroquine and amodiaquine, PfCRT 76T 
and PfMDR1 86Y, has decreased dramatically [11]. These 
changes have followed widespread adoption of ACT, in 
particular with artemether-lumefantrine, to treat uncom-
plicated malaria. Thus, it is reasonable to ascribe changes 
in genotypes to changes in drug pressure. However, some 
common polymorphisms have unclear associations with 
drug sensitivity, and so their prevalence might be better 
explained by impacts on fitness. This seems most likely 
for Y184F, which was not clearly associated with ex vivo 
drug sensitivity [10], and which maintains an interme-
diate prevalence in much of Africa. This study suggests 
that, in the context of heavy use of chloroquine, the 
184F mutation persisted due to fitness advantages of 
the YF haplotype over the NF haplotype. More recently, 
with reversion to N86 wild type parasites, likely due 
to decreased selective pressure from chloroquine and 
increased pressure from lumefantrine, it is reasonable to 
expect that the 184F mutation would decrease in preva-
lence, but in Uganda the prevalence of this polymor-
phism has remained fairly stable in recent years [37, 38]. 
Fitness impacts of PfMDR1 polymorphisms should be 
considered in light of other polymorphisms that have also 
been shown to affect drug sensitivity and/or fitness, most 
notably the PfMDR1 D1246Y and PfCRT 76T mutations 
[39], but also other PfCRT mutations recently identified 
in southeast Asian parasites [40, 41], and mediators of 
artemisinin resistance in southeast Asia [42–44]. The ina-
bility to produce parasites with a stable PfMDR1 1246Y 
mutation capable of in vitro growth was highly suggestive 
of diminished fitness for mutant parasites, but this find-
ing prevented comparison of fitness using competitive 
growth experiments.
It is important to put these results in a clinical con-
text, considering widespread treatment of malaria with 
ACT (primarily artemether-lumefantrine) in Africa. 
Clinical trials have shown continued excellent efficacy 
for leading artemisinin-based combinations across Africa 
[45–47]. However, in Uganda relative loss of efficacy of 
artemether-lumefantrine compared to artesunate-amodi-
aquine was seen, consistent with the genotypic changes 
seen in recent years [45]. These new results suggest that 
the PfMDR1 86Y chloroquine/amodiaquine resistance 
mutation is stabilized in the presence of specific PfMDR1 
haplotypes, but that drug pressure strongly influences 
selection of parasite genotypes. As noted above, with 
widespread utilization of artemether-lumefantrine, 
the 86Y mutation is disappearing, indicating selective 
pressure in the field consistent with that seen in these 
co-culture experiments, and modestly decreasing the 
anti-malarial efficacy of artemether-lumefantrine [45].
This study had important limitations. Although com-
parison of isogenic lines differing only at introduced 
loci provides assurance that the impacts of the intro-
duced polymorphisms were compared, relative growth 
in culture may not be representative of relative fitness 
during human infections. The studied parasites were 
the products of a cross between African and Brazil-
ian clones; arguably consideration of African parasites 
may have yielded results more relevant for drug resist-
ance in Africa. It was not possible to study all PfMDR1 
mutations commonly circulating in African parasites, 
as stable parasites with the PfMDR1 1246Y mutation 
could not be produced. The whole genome sequences 
of transfected parasites were not compared; it is pos-
sible, though unlikely, that additional mutations that 
occurred by chance during the transfection process may 
have impacted on parasite fitness. Most importantly, 
multiple factors impact upon parasite survival in clini-
cal infections, including inherent parasite fitness, host 
immunity, multiplicity of infection, drug pressure over 
the course of infection, and host genetics. In this con-
text, these experiments have limited ability to predict 
the haplotypes that will emerge and become stable over 
time, but it is of interest that these results are generally 
consistent with the patterns of drug use and haplotype 
prevalence in Africa. However, while it was demonstrated 
that the PfMDR1 184F mutation stabilizes the 86Y muta-
tion, these data cannot explain the persistence of 184F as 
86Y has disappeared in Uganda in recent years. Deeper 
understanding of responses to additional selective envi-
ronments will be necessary to better understand and pre-
dict evolutionary outcomes.
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Conclusions
In summary, varied impacts on fitness of PfMDR1 poly-
morphisms were associated with altered drug sensitiv-
ity. Notably, the 86 N wild type that mediates decreased 
sensitivity to lumefantrine had decreased fitness in the 
setting of the 184 F mutation compared to the Y184 wild 
type. An appreciation of the contributions of different 
polymorphisms and haplotypes to parasite fitness can 
help us to predict changes in parasites under the pressure 
of anti-malarial drug use, and thus to best utilize avail-
able drugs to treat and control malaria.
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